Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial

医学 痛风 内科学 不利影响 痹症科 秋水仙碱 别嘌呤醇 随机对照试验 临床试验 外科 安全概况 物理疗法 生活质量(医疗保健) 非甾体 高尿酸血症
作者
Zaihua Zhu,Yu Xue,Tianshu Chu,Jiankang Hu,Wei Gou,Ning Zhang,Juan Li,Jing Yu,Rongping Li,Rongbin Li,Long Qian,Xinwang Duan,Lihua Duan,Qian Xu,Fei Gu,Yuling Lian,Xu Zhang,Hejian Zou
出处
期刊:Advances in Therapy [Adis, Springer Healthcare]
标识
DOI:10.1007/s12325-026-03611-6
摘要

INTRODUCTION: Patients with recurrent acute gout flares who are unable to use nonsteroidal anti-inflammatory drugs (NSAIDs) or colchicine have limited alternatives and remain at high risk of flare recurrence. Firsekibart is a fully human monoclonal antibody targeting interleukin-1βeta (IL-1β) The objective of this study is to evaluate the longer-term efficacy and safety of firsekibart through 48 weeks in patients with acute gout unsuitable for standard anti-inflammatory therapy. METHODS: This was a multicenter, randomized, double-blind, positive-controlled phase 3 study of firsekibart with compound betamethasone. Followed by a 24-week open-label extension (OLE), conducted at hospitals in China. The double-blind phase was conducted from Week 0 to Week 24, followed by an OLE through Week 48 and a 12-week safety follow-up period after the last dose. Adults with ≥ 2 acute gout flares in the past year and a contraindication, intolerance, or inadequate response to NSAIDs and/or colchicine were enrolled. Patients completing the double-blind phase entered the OLE, during which firsekibart was administered for acute gout flares as needed. Efficacy included proportion of patients experiencing ≥ 1 gout flare recurrence, number of flares per patient, and time to first recurrence through Week 48, as well as rescue medication use during the OLE. Exploratory outcomes included health-related quality of life and flare-related pain. Safety included adverse events (AEs), laboratory tests, and immunogenicity. RESULTS: Of 313 patients (double-blind phase), 300 entered the OLE. By week 48, gout flare recurrence occurred in 70 patients (44.9%) in the firsekibart group compared with 116 (74.8%) in the positive control group (difference - 29.97%; 95% CI - 40.228% to - 18.544%). Kaplan-Meier analysis showed that the median time to first recurrence was not reached with firsekibart versus 37 days with positive control, indicating a 70% [hazard ratio (HR) 0.30; 95% confidence interval (CI) 0.223, 0.408; stratified log rank P < 0.0001] lower recurrence risk. Firsekibart maintained efficacy through Week 48. Treatment-emergent adverse events were reported in 89.7% of patients in the firsekibart group and 89.1% in the positive control group, with no new safety signals identified during extended follow-up. CONCLUSION: In this open-label extension study, firsekibart demonstrated sustained efficacy in reducing gout flare recurrence through 48 weeks, with a consistent and favorable safety profile, and no new safety signals identified during extended follow-up. TRIAL REGISTRATION: NCT05983445.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
MRCHONG完成签到,获得积分10
1秒前
Jay完成签到,获得积分10
2秒前
Tonue发布了新的文献求助10
2秒前
南星完成签到,获得积分10
2秒前
3秒前
情怀的应助被踏实博超采纳,获得10
3秒前
3秒前
yuan完成签到,获得积分10
3秒前
ding的应助被坚定的羽毛采纳,获得10
3秒前
3秒前
4秒前
4秒前
壮观梦易发布了新的文献求助10
4秒前
乡非农卡完成签到,获得积分10
4秒前
5秒前
5秒前
6秒前
募雨qaq完成签到,获得积分10
6秒前
6秒前
mate发布了新的文献求助30
7秒前
懵懂的映菱完成签到,获得积分10
8秒前
ccccc完成签到 ,获得积分10
8秒前
桃子汽水发布了新的文献求助10
8秒前
阳利发布了新的文献求助10
8秒前
科目三的应助被夏目采纳,获得20
8秒前
8秒前
紧张的道消完成签到 ,获得积分10
9秒前
9秒前
初景发布了新的文献求助10
9秒前
20030419ty2完成签到,获得积分10
9秒前
9秒前
lsx发布了新的文献求助10
9秒前
9秒前
屹男发布了新的文献求助10
9秒前
9秒前
米饭发布了新的文献求助10
10秒前
10秒前
今后的应助被科研通管家采纳,获得10
10秒前
桐桐的应助被科研通管家采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183739
求助须知:如何正确求助?哪些是违规求助? 9572996
关于积分的说明 21828615
捐赠科研通 7780904
什么是DOI,文献DOI怎么找? 3434101
关于科研通互助平台的介绍 2558294
邀请新用户注册赠送积分活动 2480564